	US 12,280,049 B2
	Methods of delaying pain progression and treating prostate cancer
Jinyu Kang, Wilmington, DE (US)
Assigned to ASTRAZENECA AB, Sodertalje (SE)
Filed by ASTRAZENECA AB, Sodertalje (SE)
Filed on Aug. 3, 2021, as Appl. No. 17/392,676.
Claims priority of provisional application 63/060,962, filed on Aug. 4, 2020.
Prior Publication US 2022/0040173 A1, Feb. 10, 2022
Int. Cl. A61K 31/502 (2006.01); A61K 31/498 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01)

CPC A61K 31/502 (2013.01) [A61K 31/498 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01)]

18 Claims

1. A method for delaying pain progression in a subject receiving treatment for prostate cancer, the method comprising:

administering to the subject a therapeutically effective amount of 4-[(3-{[4-(cyclopropane-carbonyl) piperazine-1-yl]carbonyl}-4-fluorophenyl) methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof, wherein the therapeutically effective amount of olaparib is about 600 mg daily; then

identifying the subject as having pain progression as evaluated by a pain questionnaire or an opioid use log and administering to the subject a therapeutically effective amount of an opiate;

wherein the time to pain progression in the subject is delayed by at least 10 months as compared to the time to pain progression in a subject receiving the standard of care treatment; and

wherein the administration of the opiate to the subject is delayed by at least 10 months as compared to administration of an opiate in a subject receiving the standard of care treatment.